TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T01928 XX ID T01928 XX DT 04.11.1996 (created); ewi. DT 23.11.2012 (updated); prb. CO Copyright (C), QIAGEN. XX FA Bcl-3 XX SY B-cell leukemia/lymphoma 3; Bcl3. XX OS human, Homo sapiens OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; primates XX GE G004492 BCL3; HGNC: Bcl3. XX CL C0020; Rel; XX SF N- and C-terminally adjacent to the ankyrin repeats is a trans-activating region [8]; SF ankyrin repeats are sufficient for binding to p50 homodimers [9] [11]; SF N-terminally intact Bcl-3 is required for specific inhibition of p50/p52 heterodimers [9]; XX FF transcriptional activator; FF inhibition of DNA-binding of NF-kappaB1 (p50) homodimers and dissociating them from DNA [3] [4] [9] [11] [13] [14]; FF forming a ternary activating complex with NF-kappaB2 (p52) homodimers [3] [7] [8]; FF conflicting results on the Bcl-3 effect on p50, possibly due to differences in the phosphorylation status of Bcl-3 [2] [3] [6] [10]; FF proto-oncogene, may be involved in chromosomal translocations causing B-cell leukemias [1]; XX IN T06040 CtBP2; human, Homo sapiens. IN T00593 NF-kappaB1-p50; human, Homo sapiens. IN T00394 NF-kappaB2-p52; human, Homo sapiens. IN T01923 p50; mouse, Mus musculus. IN T28757 TBLR1; human, Homo sapiens. XX MX M04816 V$BCL3_03. XX DR TRANSPATH: MO000019320. DR UniProtKB: P20749; XX RN [1]; RE0002005. RX PUBMED: 2566973. RA Fujita T., Miyamoto M., Kimura Y., Hammer J., Taniguchi T. RT Involvement of a cis-element that binds an H2TF-1/NFkappaB like factor(s) in the virus-induced interferon-beta gene expression RL Nucleic Acids Res. 17:3335-3346 (1989). RN [2]; RE0004492. RX PUBMED: 8196632. RA Zhang Q., Didonato J. A., Karin M., McKeithan T. W. RT BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappaB proteins RL Mol. Cell. Biol. 14:3915-3926 (1994). RN [3]; RE0004493. RX PUBMED: 7559449. RA Pan J., McEver R. P. RT Regulation of the human P-selection promoter by Bcl-3 and specific homodimeric members of the NF-kappaB/Rel family RL J. Biol. Chem. 270:23077-23083 (1995). RN [4]; RE0004508. RX PUBMED: 1532257. RA Hatada E. N., Nieters A., Wulczyn F. G., Naumann M., Meyer R., Nucifora G., McKeithan T. W., Scheidereit C. RT The ankyrin repeat domains of the NF-kappaB precursor p105 and the protooncogene bcl-3 act as specific inhibitors of NF- kappaB DNA binding RL Proc. Natl. Acad. Sci. USA 89:2489-2493 (1992). RN [5]; RE0004509. RX PUBMED: 8428580. RA Naumann M., Wulczyn F. G., Scheidereit C. RT The NF-kappaB precursor p105 and the proto-oncogene product Bcl-3 are IkappaB molecules and control nuclear translocation of NF-kappaB RL EMBO J. 12:213-222 (1993). RN [6]; RE0004510. RX PUBMED: 8330739. RA Fujita T., Nolan G. P., Liou H.-C., Scott M. L., Baltimore D. RT The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappaB p50 homodimers RL Genes Dev. 7:1354-1363 (1993). RN [7]; RE0004519. RX PUBMED: 1740105. RA Ten R. M., Paya C. V., Israel N., Le Bail O., Mattei M.-G., Virelizier J.-L., Kurilsky P., IsraNl A. RT The characterization of the promoter of the gene encoding the p50 subunit of NF-kappaB indicates that it participates in its own regulation RL EMBO J. 11:195-203 (1992). RN [8]; RE0004533. RX PUBMED: 8453667. RA Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., Siebenlist U. RT The oncoprotein Bcl-3 directly transactivates through kappaB motifs via association with DNA-binding p50B homodimers RL Cell 72:729-739 (1993). RN [9]; RE0004617. RX PUBMED: 1459457. RA Kerr L. D., Duckett C. S., Wamsley P., Zhang Q., Chiao P., Nabel G., McKeithan T. W., Baeuerle P. A., Verma I. M. RT The proto-oncogene BCL-3 encodes an IkappaB protein RL Genes Dev. 6:2352-2363 (1992). RN [10]; RE0004618. RX PUBMED: 8497270. RA Nolan G. P., Fujita T., Bhatia K., Huppi C., Liou H.-C., Scott M. L., Baltimore D. RT The bcl-3 proto-oncogene encodes a nuclear IkappaB-like molecule that preferentially interacts with NF-kappaB p50 and p52 in a phosphorylation-dependent manner RL Mol. Cell. Biol. 13:3557-3566 (1993). RN [11]; RE0004619. RX PUBMED: 8404857. RA Franzoso G., Bours V., Azarenko V., Park S., Tomita-Ymaguchi M., Kanno T., Brown K., Siebenlist U. RT The oncoprotein Bcl-3 can facilitate NF-kappaB mediated transactivation by removing inhibiting p50 homodimers from select kappaB sites RL EMBO J. 12:3893-3901 (1993). RN [12]; RE0004620. RX PUBMED: 2180580. RA Ohno H., Takimoto G., McKeithan T. W. RT The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell-cycle control RL Cell 60:991-997 (1990). RN [13]; RE0004621. RX PUBMED: 1501714. RA Wulczyn F. G., Naumann M., Scheidereit C. RT Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappaB RL Nature 358:597-599 (1992). RN [14]; RE0004622. RX PUBMED: 1406939. RA Franzoso G., Bours V., Park S., Tomita-Yamaguchi M., Kelly K., Siebenlist U. RT The candidate oncoprotein bcl-3 is an antagonist of p50/NF-kappaB-mediated inhibition RL Nature 359:339-342 (1992). RN [15]; RE0004641. RX PUBMED: 7896265. RA McKeithan T. W., Ohno H., Dickstein J. RT Genomic structure of the candidate proto-oncogene BCL-3 RL Genomics 247:120-126 (1994). RN [16]; RE0047796. RX PUBMED: 15469820. RA Viatour P., Dejardin E., Warnier M., Lair F., Claudio E., Bureau F., Marine J. C., Merville M. P., Maurer U., Green D., Piette J., Siebenlist U., Bours V., Chariot A. RT GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. RL Mol. Cell 16:35-45 (2004). RN [17]; RE0070618. RX PUBMED: 20547759. RA Keutgens A., Shostak K., Close P., Zhang X., Hennuy B., Aussems M., Chapelle J. P., Viatour P., Gothot A., Fillet M., Chariot A. RT The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1. RL Mol. Cell. Biol. 30:4006-4021 (2010). XX //